Consun Pharmaceutical Group Limited’s monthly return for the period ended 31 March 2026 shows a net issuance of 124,000 ordinary shares, lifting the total outstanding share count to approximately 841.55 million. The new shares, all listed on the Hong Kong Stock Exchange, stemmed exclusively from option exercises under the Share Option Scheme approved on 2 December 2013.

Authorized share capital remained unchanged at 5.00 billion ordinary shares with a par value of HKD 0.10, equivalent to HKD 500.00 million.

During the month, option holders exercised 124,000 options, reducing outstanding options under the 2013 scheme to about 7.07 million. No options were granted or exercised under the newer scheme approved on 31 May 2024. Cash proceeds from the March option exercises totaled HKD 0.50 million.

The company reported no treasury share activity; the treasury balance stood at zero. Consun Pharma confirmed that it continued to meet the Main Board’s minimum public-float requirement of 25 percent.

Management affirmed that all newly issued shares were duly authorized, fully paid, and compliant with Hong Kong listing and regulatory requirements.